A physician-supervised telehealth program is making compounded semaglutide and tirzepatide available with pricing starting at $179/month.
Sponsored by MEDVi | April 2026
If you've spent the last two years watching the GLP-1 conversation unfold from the sidelines — reading the headlines, hearing about the clinical research, maybe even asking your doctor about it — only to be stopped cold by the price, you're far from alone.
Brand-name GLP-1 medications like Ozempic and Mounjaro have dominated health news since 2023. And for good reason: this class of drugs has generated substantial interest among physicians and researchers studying weight management.
But there's been one major barrier. For millions of Americans without specific insurance coverage, the out-of-pocket cost for brand-name GLP-1 medications can run anywhere from $900 to $1,500 per month based on published list prices.
That's not sustainable for most households.
So when people hear that physician-supervised programs now exist offering compounded versions of semaglutide and tirzepatide — with pricing starting at $179 per month — the reaction is understandable: skepticism first, then curiosity.
Compounded medications are not FDA-approved and have not been tested for bioequivalence to brand-name products. Individual results vary. Not all patients will qualify.
GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces in the gut after eating. It plays a role in two key processes: signaling your brain that you're full, and helping regulate blood sugar by prompting the pancreas to release insulin in response to food.
Research suggests that GLP-1 signaling efficiency can vary between individuals. Some people may experience reduced or delayed satiety signals, which can make sustained weight management more difficult despite genuine effort. A licensed physician can evaluate whether GLP-1 medication may be relevant to a specific patient's situation.
GLP-1 medications like semaglutide and tirzepatide are synthetic versions of this hormone. When administered under physician supervision, they may help support appetite regulation — potentially reducing appetite, supporting healthier portion control, and helping the body manage blood sugar more effectively.
The clinical research behind FDA-approved formulations of these compounds has been widely published, and the medical community's interest is substantial. But the conversation has always circled back to one sticking point: who can actually afford them?
Let's be direct about the economics.
Brand-name Ozempic (semaglutide) carries a published list price above $900/month. Mounjaro (tirzepatide) is comparable. Insurance coverage varies — many plans exclude weight management indications entirely, and prior authorization can take weeks. Even with manufacturer coupons, costs remain out of reach for many families.
The result is a system where access to one of modern medicine's most talked-about treatment categories often depends on income or insurance plan rather than health need or a physician's recommendation.
This is the gap that programs like MEDVi were designed to address.
MEDVi is a physician-supervised telehealth program that connects eligible adults (ages 21–80, in all 50 states) with licensed physicians who evaluate whether compounded GLP-1 medications may be appropriate for their individual health profile.
Two important points up front:
Every prescribing decision is made by a licensed physician. This isn't a supplement company or a direct-to-consumer checkout flow. A licensed doctor reviews your health history, evaluates your goals and risk factors, and determines whether a compounded GLP-1 medication is medically appropriate. Not everyone will qualify — and that's by design.
The medications are compounded. Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies using semaglutide or tirzepatide as the active pharmaceutical ingredient. The physician overseeing your care makes prescribing decisions based on your individual health profile.
Eligible patients can access physician-supervised GLP-1 treatment with pricing starting at $179 per month — a lower price point than brand-name alternatives — with medication delivered directly to their door. Pricing varies by medication type (semaglutide vs. tirzepatide), dosage level, and treatment phase. The $179 figure reflects the lowest available starting price during the initial titration phase.
The process is straightforward, but it's built around a medical framework — not a shopping cart.
You fill out a comprehensive online health questionnaire covering your medical history, current medications, weight management history, and health goals. This information goes directly to a licensed physician.
A licensed physician reviews your evaluation. If they need additional information or want to discuss your history in more detail, they'll connect with you directly. The physician — not an algorithm — decides whether a compounded GLP-1 medication is appropriate for your situation.
If the physician determines that treatment is appropriate, your prescription is sent to a licensed compounding pharmacy. Your medication is prepared and shipped directly to your home.
The program includes ongoing physician oversight so your treatment can be adjusted as needed based on your response and progress. Individual results vary, and your physician works with you to determine the right approach over time.
"Is this safe?"
Every prescription in the MEDVi program is written by a licensed physician after individual evaluation. FDA-approved GLP-1 receptor agonists are among the most studied compounds in recent pharmacological history. Like all medications, they carry potential side effects — most commonly gastrointestinal symptoms like nausea, particularly during the early titration phase. Your supervising physician monitors for these and adjusts your protocol accordingly. This is why physician supervision matters and why not all patients will qualify.
Note: The safety and efficacy of compounded semaglutide and tirzepatide have not been independently evaluated by the FDA. Clinical studies commonly cited in media coverage were conducted using FDA-approved brand-name formulations.
"Why is it cheaper than brand-name?"
Brand-name pricing reflects pharmaceutical company pricing structures, patent protections, and insurance reimbursement dynamics — not just the cost of the medication itself. Compounded medications prepared by licensed pharmacies use the same active pharmaceutical ingredient but operate outside the brand-name pricing framework. Compounded medications are not FDA-approved and are not bioequivalent to brand-name formulations.
"What about insurance?"
MEDVi operates outside the insurance model, which is part of why it can offer more accessible pricing. There are no prior authorization delays, no coverage denials, and no waiting to find out if your plan covers weight management. Pricing varies by medication, dosage, and treatment phase.
"Will this work for me?"
Individual results vary — that's the straightforward answer, and anyone promising a specific number of pounds is not being honest with you. Clinical trials on FDA-approved GLP-1 receptor agonists have shown that these medications can support meaningful weight management when combined with lifestyle modifications like improved nutrition and increased physical activity. However, clinical trial results for brand-name formulations may not be directly applicable to compounded versions. Your physician will help set realistic expectations based on your specific health profile.
Compounded medications are not FDA-approved. Individual results vary. Not all patients will qualify. This is a paid advertisement.
MEDVi may be worth exploring if you're an adult between 21 and 80 who has struggled with weight management despite genuine effort with diet and exercise, and who has found brand-name GLP-1 options financially out of reach.
It's likely not the right path if you're looking for a shortcut without any commitment to healthier habits, or if you have medical conditions that may contraindicate GLP-1 use. That's exactly why the physician evaluation exists — to determine whether this is appropriate for you specifically.
Interest in GLP-1 medications for weight management continues to grow, driven by published clinical research on FDA-approved formulations. The question is increasingly about access: who can afford these treatments?
Programs like MEDVi are part of a growing effort to expand that access. Physician-supervised. More affordably priced. Available nationwide. With pricing starting at $179/month, varying by medication and dosage.
If you've been looking for a more accessible way to explore whether GLP-1 treatment might be right for you, this program may be worth discussing with a physician.
Compounded medications are not FDA-approved. Individual results vary. Not all patients will qualify. This is a paid advertisement.